Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04710212 Completed - Clinical trials for Hematologic Malignancy

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

SCENE
Start date: March 12, 2021
Phase:
Study type: Observational

This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with fluoroquinolone-resistant Enterobacterales (FQRE) and the clinical impact of FQRE colonization.

NCT ID: NCT04709445 Recruiting - Ulcerative Colitis Clinical Trials

Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

In this prospective, non-randomized cohort study, real-time intraoperative visualization using near-infrared-fluorescence by indocyanine green injection (ICG-NIRF) is performed at two to three time points during procedures of upper GI, lower GI and hepatobiliary surgery with anastomosis formation in open or laparoscopic surgery. Postoperatively, a detailed software-based assessment of each recording is performed to determine the objective ICG-NIRF perfusion rate before and after anastomosis formation, which is then correlated with the 30 day postoperative clinical outcome including occurrence of anastomotic leak.

NCT ID: NCT04708548 Completed - Quality of Life Clinical Trials

Long Term Implications of Rare Brain Tumours'

Start date: May 29, 2020
Phase:
Study type: Observational

Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 and 12 years). These patients are often treated with surgery, chemotherapy and/or radiotherapy. However, as patients live for a long period of time, they may also experience long-term toxic side-effects of treatment. The long-term consequences of treatment- and disease-related factors on quality of life and cognitive functioning of these patients are largely unknown. This study aims to investigate quality of life and cognitive functioning in long-term survivors of oligodendroglioma (with IDH mutation and 1p/19q codeletion). This knowledge can support health care professionals prepare patients for any long-term consequences of treatment.

NCT ID: NCT04708210 Active, not recruiting - Clinical trials for Advanced Malignant Tumors

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Start date: April 28, 2021
Phase: Phase 1
Study type: Interventional

An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and preliminary efficacy of IBI319 in patients with advanced malignant tumors

NCT ID: NCT04707365 Not yet recruiting - Colorectal Cancer Clinical Trials

Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort

MICADO
Start date: March 2021
Phase: N/A
Study type: Interventional

Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study

NCT ID: NCT04707300 Recruiting - Clinical trials for Hematologic Malignancy

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

HTLP-ONCO
Start date: February 16, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.

NCT ID: NCT04707196 Completed - Breast Neoplasms Clinical Trials

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Start date: February 22, 2021
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with hormone therapy in Indian women with advanced breast cancer. Participants must have hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer and must live in India. For each participant, the study could last up to eight months and may include up to eight visits to the study center.

NCT ID: NCT04706676 Recruiting - Lymphoma Clinical Trials

Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer

INTERACT
Start date: January 26, 2021
Phase: N/A
Study type: Interventional

The INTERACT study is a nation-wide, population-based randomized controlled trial to investigate the effects of 6-month integrative neuromuscular training during anti-cancer treatment on lower body muscle strength, metabolic syndrome, various measures of physical function, physical activity, days of hospitalization, health-related quality of life and health behavior in children and adolescents with cancer. The increased insight derived from this study will impact the development of pediatric exercise oncology and be of high relevance to a broad group of children and adolescents with severe chronic illness. The study is based on the overarching hypothesis, that structured integrative neuromuscular training initiated immediately after diagnosis will be effective in preventing deficits in neuromuscular function, limit long-term cardio-metabolic morbidity and found long-standing improvements in physical activity behavior. To maintain adherence and motivation throughout a 6-month training intervention, weekly supervision of the training is needed. For this study, it is hypothesized that a supervised exercise intervention, in addition to a motivational counseling intervention and usual care, will improve muscle strength compared with unsupervised home-based training (active controls).

NCT ID: NCT04705818 Recruiting - Clinical trials for Advanced Solid Tumor

Combining Epigenetic And Immune Therapy to Beat Cancer.

CAIRE
Start date: July 23, 2021
Phase: Phase 2
Study type: Interventional

Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

NCT ID: NCT04704908 Active, not recruiting - Cervical Cancer Clinical Trials

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Start date: February 6, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the standard 3-dose schedule (0,1,6 months).